Clifford Chance advises Luxinva on QIAGEN takeover
The firm represents Luxinva in the €10.8 billion voluntary public offer for molecular diagnostics leader QIAGEN.
See the latest news and media coverage for Clifford Chance. We track all announcements, press releases, and industry mentions in real time, all in one place.
Global law firm
cliffordchance.comLast updated
In short: Clifford Chance advised on major deals, hired partners, and ranked first in European M&A during Q3 2026.
The firm represents Luxinva in the €10.8 billion voluntary public offer for molecular diagnostics leader QIAGEN.
Revenue up 9% to £2.6bn, profit up 11% to £1.05bn, and PEP up 9% to £2.3m, with growth across all regions and products.
The firm handled antitrust and regulatory matters, led by partners Nelson Jung and Stavroula Vryna.
It acted as U.S. and New York counsel on the Rule 144A/Reg S five-year offering used to repay loans and support general corporate purposes.
Clifford Chance is targeting continued and accelerated growth in the US, according to managing partner Charles Adams, with another set of positive financial results putting...
The international firm closed its fiscal year with a profit of 1.05 billion pounds and a 9% increase in profit per partner ...
Clifford Chance partners took home a record £2.3mn last year despite a slowdown in US revenue growth. The UK "magic circle" firm saw its partner...
Sidley Austin is adding to its haul of US partners from Clifford Chance, poaching a five-partner group in New York and Washington. Lee Askenazi, who...
Track Clifford Chance and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Clifford Chance and other trending companies.